Review
Clinical Neurology
Melani J. Boyce, Alana B. McCambridge, Lynley Bradnam, Colleen G. Canning, Arianne P. Verhagen
Summary: The study identified direct barriers to satisfaction with BoNT therapy for CD including treatment non-response, negative side effects, early wearing-off of treatment effect, and inexperience of the treating physician. Indirect barriers included limited accessibility to treatment and personal choice. Facilitators of satisfaction with BoNT therapy included relief of symptoms and flexible re-treatment intervals, while indirect facilitators included easy accessibility to treatment.
NEUROLOGICAL SCIENCES
(2022)
Review
Food Science & Technology
Urban M. Fietzek, Devavrat Nene, Axel Schramm, Silke Appel-Cresswell, Zuzana Kosutzka, Uwe Walter, Joerg Wissel, Steffen Berweck, Sylvain Chouinard, Tobias Baeumer
Summary: Visualization of the human body, especially through the use of ultrasound (US) imaging, has become a well-established procedure for botulinum toxin therapy in people with cervical dystonia (CD). This technique allows safe injection of relevant muscles under visual US guidance and provides personalized treatment for patients with CD.
Article
Food Science & Technology
Matteo Costanzo, Daniele Belvisi, Isabella Berardelli, Annalisa Maraone, Viola Baione, Gina Ferrazzano, Carolina Cutrona, Giorgio Leodori, Massimo Pasquini, Antonella Conte, Giovanni Fabbrini, Giovanni Defazio, Alfredo Berardelli
Summary: Botulinum toxin type A (BoNT-A) effectively improves non-motor symptoms in patients with cervical dystonia (CD), such as psychiatric disturbances, pain, and disability, while having no impact on sleep disorders. The motor and non-motor changes induced by BoNT-A show a similar time course, but are independent of each other.
Article
Clinical Neurology
Martina Petracca, Maria Rita Lo Monaco, Tamara Ialongo, Enrico Di Stasio, Maria Luana Cerbarano, Loredana Maggi, Alessandro De Biase, Giulia Di Lazzaro, Paolo Calabresi, Anna Rita Bentivoglio
Summary: Botulinum toxin A (BoNT/A) is a first-line treatment for idiopathic cervical dystonia (ICD), but there is limited data on its effectiveness for acquired cervical dystonia (ACD). This long-term follow-up study showed that all serotypes of BoNT have lasting efficacy and safety in treating ACD, even after 25 years of repeated treatments.
JOURNAL OF NEUROLOGY
(2023)
Article
Food Science & Technology
Farris Kassam, Brendan Lim, Sadia Afroz, Eve Boissonnault, Rajiv Reebye, Heather Finlayson, Paul Winston
Summary: Spasticity of the upper extremity can cause severe pain and complications, leading to impaired daily activities. Canadian physicians utilize Botulinum toxin type-A injections for the management of shoulder spasticity, with varying practice patterns and dosing. The most commonly injected muscles are pectoralis major, latissimus dorsi, pectoralis minor, subscapularis, and teres major. Future studies are needed to standardize care and develop optimal treatment patterns.
Article
Clinical Neurology
Dana Sugar, Roshni Patel, Cynthia Comella, David A. Gonzalez, Gabrielle Gray, Glenn T. Stebbins, Abhimanyu Mahajan
Summary: This study evaluated the impact of botulinum toxin on anxiety symptoms in patients with cervical dystonia. The results showed that botulinum toxin not only improved the severity of motor symptoms, but also reduced anxiety symptoms.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Medicine, General & Internal
Stefan Evers, Alexandra Buchheister, Doris Reichelt, Ingo W. Husstedt, Achim Frese
Summary: This study investigated the efficacy and safety of BTX treatment in HIV-infected patients. The results showed that BTX treatment was effective and well-tolerated in long-term use, with no interaction with antiretroviral treatment. Therefore, BTX treatment can be considered as an additional therapeutic option for HIV-infected patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Neurosciences
Michal Marciniec, Anna Szczepanska-Szerej, Ewa Papuc, Konrad Rejdak
Summary: Cervical pain is a common non-motor symptom of cervical dystonia (CD) that affects a majority of patients. This study found that cervical pain may increase the severity of muscular symptoms and disease-related disability. Botulinum toxin has a noticeable antinociceptive effect in the long-term treatment of CD.
INTERNATIONAL JOURNAL OF NEUROSCIENCE
(2022)
Article
Behavioral Sciences
Malgorzata Dec-Cwiek, Karolina Porebska, Katarzyna Sawczynska, Marcin Kubala, Magdalena Witkowska, Kinga Zmijewska, Jakub Antczak, Joanna Pera
Summary: This study aimed to investigate the efficacy of kinesiology taping as an adjunct to botulinum toxin injections in patients with cervical dystonia. The results showed that kinesiology taping had no additional effect on the severity of dystonia, but it improved the quality of life in patients with CD. Further research is needed to explore the effect of kinesiology taping prior to botulinum toxin injections.
BRAIN AND BEHAVIOR
(2022)
Article
Clinical Neurology
Cynthia Comella, Joaquim J. Ferreira, Emilie Pain, Marion Azoulai, Savary Om
Summary: The survey reveals the heavy burden of CD symptoms, even in patients receiving regular treatment. Symptom re-emergence is common and significantly impacts daily activities and quality of life.
JOURNAL OF NEUROLOGY
(2021)
Article
Medicine, Research & Experimental
Michael Hull, Vamshi Ruthwik Anupindi, Mitchell DeKoven, Jing He, Jonathan Bouchard
Summary: Spasticity and cervical dystonia have a significant impact on quality of life and economic burden. This study analyzed healthcare claims to understand the treatment patterns, healthcare resource utilization, and costs among patients with these conditions. The results showed that botulinum toxin type A injections were effective in reducing muscle tightness and improving range of motion.
ADVANCES IN THERAPY
(2023)
Article
Food Science & Technology
Mariam Hull, Mered Pames, Joseph Jankovic
Summary: Opisthotonus is a condition characterized by abnormal trunk extension and arching due to excessive contractions of the paraspinal muscles. It is most commonly seen in children with dystonia secondary to hypoxic injury or other acquired and genetic causes. Treatment options include oral medications, muscle injections, and deep brain stimulation, although management in the pediatric population has not been systematically reviewed.
Article
Clinical Neurology
Yaowen Hu, Lizhen Pan, Junhui Su, Shuzhen Chen, Xiaolong Zhang, Yougui Pan, Lingjing Jin, Fei Teng
Summary: This study characterized the target muscles involved in retroform cervical dystonia (RCD) and evaluated the efficacy of botulinum toxin type A (BTX-A) injection. The most frequently injected muscles in RCD were splenius capitis, semispinalis capitis, levator scapulae, rectus capitis posterior major, trapezius, and sternocleidomastoid muscle. BTX-A injection achieved a satisfactory therapeutic effect in RCD, with a symptom relief rate of 69.0 +/- 16.7%.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Melani J. Boyce, A. B. Mccambridge, L. V. Bradnam, C. G. Canning, C. Quel De Oliveira, A. P. Verhagen
Summary: This study examines the use of botulinum neurotoxin (BoNT) and conservative treatments in patients with cervical dystonia. The survey found that most participants received regular BoNT injections and perceived heat packs, exercise, massage, physiotherapy, and relaxation as effective in reducing symptoms.
JOURNAL OF NEURAL TRANSMISSION
(2023)
Article
Food Science & Technology
Andre Lee, Jabreel Al-Sarea, Eckart Altenmuller
Summary: The study found that for patients with musician's dystonia, BoTX dosage and inter-injection intervals show nonlinear changes with treatment duration, while the number of injected muscles continues to increase. Two distinct subgroups were identified, with the low-BoTX group showing improvement in symptoms with continued treatment. This indicates a potential relationship between treatment response and BoTX dosages in patients with task-specific dystonias.